← All trials
NCT01449045
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Dec 1, 2011
- Completion date
- Feb 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 4554
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Cheikh Anta Diop University, SenegalLead sponsor
- Cheikh Anta Diop University, SenegalStudy director
- Cheikh Anta Diop University, SenegalStudy chair
- University of LondonStudy chair
- University of LondonCollaborator
- Cheikh Anta Diop University, SenegalReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.